Adaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
